WednesdayMar 10, 2021 8:59 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as a treatment for mild-to-moderate OSA, sleep-disordered breathing and snoring in adults. The company’s oral appliance is an updated version of the company’s existing mRNA appliance(R), which previously received FDA clearance as a Class II oral appliance. The company noted that once it received approval for the…

Continue Reading

FridayMar 05, 2021 10:43 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Establishes Clinical Advisory Board to Help Drive Growth

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), announced the creation of its new Clinical Advisory Board. The six-member board will focus on driving adoption and growth of Vivos’ next-gen treatments for OSA. Reports indicate that an estimated 1 billion people around the world struggle with OSA. Members of Vivos’ new board include the following: neurologist and sleep specialist Clete A. Kushida, MD, PhD; nationally recognized key opinion leader Edward Zuckerberg, DDS; co-founder of the American Academy of Physiological Medicine and Dentistry…

Continue Reading

WednesdayFeb 10, 2021 1:58 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Secures $24.2M in Initial Public Offering

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, has closed its initial public offering of 4,025,000 shares of its common stock, including an additional 525,000 shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Vivos Therapeutics secured approximately $24.2 million in gross proceeds, with each of the shares sold at the public offering price of $6.00. The common stock shares began trading on the Nasdaq Capital Market under the ticker symbol "VVOS" on Friday, Dec. 11, 2020. ROTH Capital Partners…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered